A large study by researchers at Stanford Medicine has found that the risk of secondary blood cancers after CAR-T cell therapy -; a cell-based cancer treatment that exploded on the scene in 2017 as a treatment for intractable blood cancers -; is low, despite a Food and Drug Administration warning.